Developer docs
API playgroundTry for free, no card

Search company profiles

FoRx Therapeutics

Full company profile

uuid0002npa

Namestring
FoRx Therapeutics
Legal namestring
FoRx Therapeutics AG
Company typeenum
Private
Founded yearint
2019
Descriptiontext

FoRx Therapeutics AG is a privately held clinical-stage biotechnology company headquartered in Basel, Switzerland, founded in 2019 by Prof. Thanos Halazonetis and Dr. Sotirios K. Sotiriou to develop precision therapeutics targeting DNA Replication Stress in treatment-resistant cancers. The company's pipeline consists of orally available small molecule inhibitors aimed at DNA Damage Response (DDR) deficiencies, with lead asset FORX-428, a proprietary poly (ADP-ribose) glycohydrolase (PARG) inhibitor, having received FDA IND clearance on June 13, 2025 and initiated first-in-human dosing on August 6, 2025 in the United States. The pipeline also includes FORX-002, a first-in-class DDR modulator in lead optimization, and FORX-003, a novel replication stress target in lead identification.

The scientific thesis exploits the vulnerability of cancer cells with high oncogene-induced replication stress or HRD-positive status to PARG inhibition, including tumors that have acquired resistance to PARP inhibitors. Preclinical data position FORX-428 as a potential best-in-class compound, with at least 10-fold higher potency than competitor reference compounds, favorable pharmacokinetics, and robust activity in hard-to-treat tumor models. The company has assembled a leadership team with deep DDR drug discovery credentials: CSO Frank Zenke was previously Global Head of DDR Research at Merck KGaA/EMD Serono, VP Chemistry Ulrich Lücking invented Bayer's clinical ATR inhibitor BAY 1895344, CMO Jens Würthner led clinical development of loncastuximab tesirine (Zynlonta) at ADC Therapeutics, and CEO Tarig Bashir previously led discovery at Proteros.

As a pre-revenue clinical-stage company, FoRx generates no commercial revenue today. Its business model is to advance FORX-428 through Phase 1 development and pursue strategic licensing or co-development agreements with larger pharmaceutical partners for global commercialization, with initial Phase 1 data expected mid-2026. Capital has been provided by a strategic-investor-heavy syndicate, with a EUR 10 million seed round in April 2020 and a USD 50 million insider-led Series A closed in December 2025, led by EQT Life Sciences with participation from Pfizer Ventures, Novartis Venture Fund, and M Ventures. Board representation from these same investors points to active preparation for a future partnership or out-licensing transaction.

Short descriptiontext

FoRx Therapeutics AG is a Swiss clinical-stage biotechnology company developing first- and best-in-class small molecule inhibitors targeting DNA replication stress and DNA damage response pathways for treatment-resistant advanced solid tumors, with lead asset FORX-428 in Phase 1 trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
PARG inhibitors, DNA damage response, small molecule oncology, oncology therapeutics, clinical-stage biotech
Industry1 code
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company. The company is developing FORX-428 through Phase 1 clinical trials with plans to commercialize through potential licensing partnerships with pharmaceutical companies or by building commercial infrastructure. Revenue would be generated through product sales following regulatory approval.

forxtherapeutics.com
2Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

The company may pursue co-development agreements, licensing deals, or strategic partnerships with larger pharmaceutical companies for the development and commercialization of its pipeline compounds.

forxtherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

FoRx Therapeutics develops small molecule precision oncology drugs that target DNA Replication Stress and the DNA Damage Response in treatment-resistant cancers. Its lead asset, FORX-428, is an orally available PARG inhibitor in Phase 1 clinical trials for advanced solid tumors, supported by earlier-stage programs FORX-002 and FORX-003 targeting additional DNA replication stress vulnerabilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • FORX-428 demonstrated at least 10-fold higher potency across multiple solid tumor cell lines compared to competitor reference compound in preclinical studies
+3 more records
Product overview1 text field

FoRx Therapeutics is a privately held clinical-stage biotechnology company pioneering precision therapeutics targeting DNA Replication Stress in treatment-resistant cancers. The company's pipeline consists of three small molecule programs: FORX-428 (lead PARG inhibitor in Phase 1 clinical testing for advanced solid tumors), FORX-002 (DDR modulator in lead optimization), and FORX-003 (replication stress target in lead identification). The company focuses on developing first- and best-in-class compounds for cancer treatment by targeting key molecular mechanisms involved in DNA replication stress and associated DNA Damage Response pathways.

Product and service3 records
1FORX-428
CategoryPARG inhibitor / oncology drug candidate
Description

An orally available, best-in-class small molecule inhibitor of poly (ADP-ribose) glycohydrolase (PARG) designed to inhibit PARG enzyme activity and induce tumor cell death in cancers with specific DNA Damage Response deficiencies or high replication stress, including HRD-positive and PARP inhibitor-resistant tumors; in Phase 1 development for patients with advanced solid tumors.

2FORX-002
CategoryDDR modulator / oncology drug candidate
Description

A first-in-class DNA Damage Response modulator in lead optimization targeting DNA replication stress in distinct types of cancer not yet addressed by other targeted DDR inhibitors.

3FORX-003
CategoryReplication stress target / oncology drug candidate
Description

A first-in-class program in lead identification targeting a unique novel target identified in screens for sensitizers to DNA replication stress, with target-selective inhibitors expected to have strong potential in tumors exhibiting high levels of oncogene-induced DNA replication stress.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Leading cancer center in the United States serving as principal investigator site for the first-in-human Phase 1 clinical trial of FORX-428. Dr. Manish R. Sharma, MD, Co-Director of Clinical Research at START Midwest, serves as Principal Investigator on the trial.

Strategic tierMinorTypeOthers
Description

FoRx Therapeutics presented the molecular structure, discovery, and preclinical data of FORX-428 at the ACS Spring 2026 meeting in Atlanta, Georgia, USA. This was the first description of the discovery and chemical structure of a clinical-stage PARG inhibitor candidate.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing synthetic lethality and DDR-targeted therapies including MAT2A, Pol theta, and Werner programs. Comparable to FoRx as a clinical-stage synthetic lethality biotech with multiple programs in early development.

TypeBroad incumbent
Description

Global pharmaceutical company and PARP inhibitor market leader via Lynparza (olaparib) co-developed with MSD, plus expanding DDR and oncology franchises. Relevant as the dominant incumbent in the patient population FoRx targets with FORX-428.

TypeBroad incumbent
Description

Global pharmaceutical company with significant DDR research and development programs (ATR, ATM, DNA-PK inhibitors) and a strategic investment in FoRx via M Ventures (Christian Uhrich on board). Both a competitive incumbent and a financial partner to FoRx.

TypeEmerging player
Description

Computational chemistry and precision oncology company with internal pipeline including DDR-targeted programs (MALT1, EGFR) and a discovery platform increasingly applied to DDR/synthetic lethality. Emerging comparable as a tech-enabled drug discovery peer intersecting with FoRx's precision oncology space.

5Artios Pharma
TypeDirect peer
Description

Private UK-based clinical-stage precision oncology company developing DDR-targeted therapies including Pol theta and ATM inhibitor programs. Directly comparable to FoRx as a European-headquartered DDR-focused biotech with multiple pipeline programs.

TypeBroad incumbent
Description

Global pharmaceutical company with broad oncology franchise including DDR programs and a strategic investment in FoRx via Novartis Venture Fund (Beat Steffen on board). Both a competitive incumbent and a financial partner with deep DDR drug discovery history.

TypeBroad incumbent
Description

Global pharmaceutical company with multiple DDR and oncology programs (Talzenna/PARP, multiple combination strategies) and a strategic investment in FoRx via Pfizer Ventures (Denis Patrick on board). Both a competitive incumbent and a financial partner.

TypeDirect peer
Description

Clinical-stage precision oncology company developing allosteric mutant-selective inhibitors across multiple oncogenic targets. Comparable to FoRx as a small-molecule precision oncology company with Phase 1/2 assets targeting defined genetic patient populations.

TypeDirect peer
Description

Clinical-stage precision oncology company developing synthetic lethality-based therapies including PRMT5 inhibitor TNG348 and multiple undisclosed synthetic lethality targets. Highly comparable business model and target approach to FoRx's DDR/replication stress focus.

TypeDirect peer
Description

Clinical-stage precision oncology company developing synthetic lethality-based therapies including POLQ inhibitor RP-3467 and multiple DDR programs. Directly comparable to FoRx as a US/Canada-based biotech with Phase 1-ready DDR assets targeting similar patient populations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FoRx Therapeutics

Oncology Therapeuticsforxtherapeutics.com

FoRx Therapeutics AG is a Swiss clinical-stage biotechnology company developing first- and best-in-class small molecule inhibitors targeting DNA replication stress and DNA damage response pathways for treatment-resistant advanced solid tumors, with lead asset FORX-428 in Phase 1 trials.

What FoRx Therapeutics does

FoRx Therapeutics AG is a privately held clinical-stage biotechnology company headquartered in Basel, Switzerland, founded in 2019 by Prof. Thanos Halazonetis and Dr. Sotirios K. Sotiriou to develop precision therapeutics targeting DNA Replication Stress in treatment-resistant cancers. The company's pipeline consists of orally available small molecule inhibitors aimed at DNA Damage Response (DDR) deficiencies, with lead asset FORX-428, a proprietary poly (ADP-ribose) glycohydrolase (PARG) inhibitor, having received FDA IND clearance on June 13, 2025 and initiated first-in-human dosing on August 6, 2025 in the United States. The pipeline also includes FORX-002, a first-in-class DDR modulator in lead optimization, and FORX-003, a novel replication stress target in lead identification.

The scientific thesis exploits the vulnerability of cancer cells with high oncogene-induced replication stress or HRD-positive status to PARG inhibition, including tumors that have acquired resistance to PARP inhibitors. Preclinical data position FORX-428 as a potential best-in-class compound, with at least 10-fold higher potency than competitor reference compounds, favorable pharmacokinetics, and robust activity in hard-to-treat tumor models. The company has assembled a leadership team with deep DDR drug discovery credentials: CSO Frank Zenke was previously Global Head of DDR Research at Merck KGaA/EMD Serono, VP Chemistry Ulrich Lücking invented Bayer's clinical ATR inhibitor BAY 1895344, CMO Jens Würthner led clinical development of loncastuximab tesirine (Zynlonta) at ADC Therapeutics, and CEO Tarig Bashir previously led discovery at Proteros.

As a pre-revenue clinical-stage company, FoRx generates no commercial revenue today. Its business model is to advance FORX-428 through Phase 1 development and pursue strategic licensing or co-development agreements with larger pharmaceutical partners for global commercialization, with initial Phase 1 data expected mid-2026. Capital has been provided by a strategic-investor-heavy syndicate, with a EUR 10 million seed round in April 2020 and a USD 50 million insider-led Series A closed in December 2025, led by EQT Life Sciences with participation from Pfizer Ventures, Novartis Venture Fund, and M Ventures. Board representation from these same investors points to active preparation for a future partnership or out-licensing transaction.

FoRx Therapeutics firmographics

Firmographics
Name
FoRx Therapeutics
Legal name
FoRx Therapeutics AG
Website
https://forxtherapeutics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
FoRx Therapeutics AG is a Swiss clinical-stage biotechnology company developing first- and best-in-class small molecule inhibitors targeting DNA replication stress and DNA damage response pathways for treatment-resistant advanced solid tumors, with lead asset FORX-428 in Phase 1 trials.
Ownership category
akta.pro rank

FoRx Therapeutics industry classification

Industry
Product category
Oncology Therapeutics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • PARG inhibitors
  • DNA damage response
  • Small molecule oncology
  • Oncology therapeutics
  • Clinical-stage biotech

Where FoRx Therapeutics is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

FoRx Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company. The company is developing FORX-428 through Phase 1 clinical trials with plans to commercialize through potential licensing partnerships with pharmaceutical companies or by building commercial infrastructure. Revenue would be generated through product sales following regulatory approval.
  2. Strategic Partnerships and Licensing: The company may pursue co-development agreements, licensing deals, or strategic partnerships with larger pharmaceutical companies for the development and commercialization of its pipeline compounds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

FoRx Therapeutics product offering

Product offering

Core offering

FoRx Therapeutics develops small molecule precision oncology drugs that target DNA Replication Stress and the DNA Damage Response in treatment-resistant cancers. Its lead asset, FORX-428, is an orally available PARG inhibitor in Phase 1 clinical trials for advanced solid tumors, supported by earlier-stage programs FORX-002 and FORX-003 targeting additional DNA replication stress vulnerabilities.

Product overview

FoRx Therapeutics is a privately held clinical-stage biotechnology company pioneering precision therapeutics targeting DNA Replication Stress in treatment-resistant cancers. The company's pipeline consists of three small molecule programs: FORX-428 (lead PARG inhibitor in Phase 1 clinical testing for advanced solid tumors), FORX-002 (DDR modulator in lead optimization), and FORX-003 (replication stress target in lead identification). The company focuses on developing first- and best-in-class compounds for cancer treatment by targeting key molecular mechanisms involved in DNA replication stress and associated DNA Damage Response pathways.

Differentiator

Problem solved

Functional benefit

Products and services

  • FORX-428 An orally available, best-in-class small molecule inhibitor of poly (ADP-ribose) glycohydrolase (PARG) designed to inhibit PARG enzyme activity and induce tumor cell death in cancers with specific DNA Damage Response deficiencies or high replication stress, including HRD-positive and PARP inhibitor-resistant tumors; in Phase 1 development for patients with advanced solid tumors.
  • FORX-002 A first-in-class DNA Damage Response modulator in lead optimization targeting DNA replication stress in distinct types of cancer not yet addressed by other targeted DDR inhibitors.
  • FORX-003 A first-in-class program in lead identification targeting a unique novel target identified in screens for sensitizers to DNA replication stress, with target-selective inhibitors expected to have strong potential in tumors exhibiting high levels of oncogene-induced DNA replication stress.

Quantifiable outcome

  • FORX-428 demonstrated at least 10-fold higher potency across multiple solid tumor cell lines compared to competitor reference compound in preclinical studies
  • +3 more outcomes

Companies that use FoRx Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

FoRx Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

FoRx Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • START MidwestminorStrategic or Co-development PartnerLeading cancer center in the United States serving as principal investigator site for the first-in-human Phase 1 clinical trial of FORX-428. Dr. Manish R. Sharma, MD, Co-Director of Clinical Research at START Midwest, serves as Principal Investigator on the trial.
  • American Chemical Society (ACS)minorOthersFoRx Therapeutics presented the molecular structure, discovery, and preclinical data of FORX-428 at the ACS Spring 2026 meeting in Atlanta, Georgia, USA. This was the first description of the discovery and chemical structure of a clinical-stage PARG inhibitor candidate.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

FoRx Therapeutics competitors and assessment

Company assessment

Direct peers

  • IDEAYA Biosciences: Clinical-stage precision oncology company developing synthetic lethality and DDR-targeted therapies including MAT2A, Pol theta, and Werner programs. Comparable to FoRx as a clinical-stage synthetic lethality biotech with multiple programs in early development.
  • Artios Pharma: Private UK-based clinical-stage precision oncology company developing DDR-targeted therapies including Pol theta and ATM inhibitor programs. Directly comparable to FoRx as a European-headquartered DDR-focused biotech with multiple pipeline programs.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric mutant-selective inhibitors across multiple oncogenic targets. Comparable to FoRx as a small-molecule precision oncology company with Phase 1/2 assets targeting defined genetic patient populations.
  • Tango Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based therapies including PRMT5 inhibitor TNG348 and multiple undisclosed synthetic lethality targets. Highly comparable business model and target approach to FoRx's DDR/replication stress focus.
  • Repare Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based therapies including POLQ inhibitor RP-3467 and multiple DDR programs. Directly comparable to FoRx as a US/Canada-based biotech with Phase 1-ready DDR assets targeting similar patient populations.

Broad incumbents

  • AstraZeneca: Global pharmaceutical company and PARP inhibitor market leader via Lynparza (olaparib) co-developed with MSD, plus expanding DDR and oncology franchises. Relevant as the dominant incumbent in the patient population FoRx targets with FORX-428.
  • Merck KGaA: Global pharmaceutical company with significant DDR research and development programs (ATR, ATM, DNA-PK inhibitors) and a strategic investment in FoRx via M Ventures (Christian Uhrich on board). Both a competitive incumbent and a financial partner to FoRx.
  • Novartis: Global pharmaceutical company with broad oncology franchise including DDR programs and a strategic investment in FoRx via Novartis Venture Fund (Beat Steffen on board). Both a competitive incumbent and a financial partner with deep DDR drug discovery history.
  • Pfizer: Global pharmaceutical company with multiple DDR and oncology programs (Talzenna/PARP, multiple combination strategies) and a strategic investment in FoRx via Pfizer Ventures (Denis Patrick on board). Both a competitive incumbent and a financial partner.

Emerging players

  • Schrödinger: Computational chemistry and precision oncology company with internal pipeline including DDR-targeted programs (MALT1, EGFR) and a discovery platform increasingly applied to DDR/synthetic lethality. Emerging comparable as a tech-enabled drug discovery peer intersecting with FoRx's precision oncology space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

FoRx Therapeutics social profiles

Digital presence

FoRx Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FoRx Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

FoRx Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FoRx Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FoRx Therapeutics

What does FoRx Therapeutics do?

FoRx Therapeutics develops small molecule precision oncology drugs that target DNA Replication Stress and the DNA Damage Response in treatment-resistant cancers. Its lead asset, FORX-428, is an orally available PARG inhibitor in Phase 1 clinical trials for advanced solid tumors, supported by earlier-stage programs FORX-002 and FORX-003 targeting additional DNA replication stress vulnerabilities.

Is FoRx Therapeutics a public or private company?

FoRx Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was FoRx Therapeutics founded?

FoRx Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is FoRx Therapeutics based?

FoRx Therapeutics is headquartered in Basel, Switzerland, in the Europe region.

How does FoRx Therapeutics make money?

Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are strategic Partnerships and Licensing.

Who are FoRx Therapeutics's main competitors?

Direct peers on record are IDEAYA Biosciences, Artios Pharma, Black Diamond Therapeutics, Tango Therapeutics and Repare Therapeutics. Broad incumbents are AstraZeneca, Merck KGaA, Novartis and Pfizer. Schrödinger is listed as an emerging player.

Does FoRx Therapeutics have an API?

No public API is recorded for FoRx Therapeutics.

What industry is FoRx Therapeutics in?

FoRx Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325413 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForxtherapeuticsFoRx TherapeuticsFoRx Therapeutics is a privately held clinical-stage biotechnology company developing precision therapeutics targeting DNA replication stress in treatment-resistant cancers. The company is based in Basel, Switzerland, and its team includes experts in cancer biology and drug discovery.BioWorldForx Therapeutics discloses discovery, structure of PARG inhibitor FORX-428Forx Therapeutics AG presented preclinical data on the optimization of its poly(ADP-ribose) glycohydrolase (PARG) inhibitor program, leading to the identification of FORX-428, which is currently undergoing phase I clinical trials. The company disclosed both the medicinal chemistry discovery process and the chemical structure of the compound at a scientific conference. The advancement to phase I trials indicates the drug candidate is progressing through standard clinical development stages.GlobeNewswireFoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428's Potential for Best-in-Class PARG InhibitionFoRx Therapeutics presented molecular structure, discovery, and preclinical data for its PARG inhibitor FORX-428 at the American Chemical Society Spring 2026 meeting in Atlanta. The preclinical data demonstrated at least 10-fold higher potency compared to a competitor reference compound across multiple solid tumor cell lines, with favorable selectivity, pharmacokinetics, and safety profiles supporting a best-in-class potential. The company indicated its Phase 1 trial in patients with advanced solid tumors is progressing as planned, with initial clinical data expected mid-2026.Pulse 2.0FoRx Therapeutics: $50 Million Series A Raised To Advance FORX-428FoRx Therapeutics, a clinical-stage biotech focused on precision oncology, closed a $50 million (CHF 40 million) Series A financing to advance its lead candidate FORX-428 into Phase 1 clinical development for advanced solid tumors. The round was led by existing investors EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund, and M Ventures, with the first closing occurring in June 2024 that funded the IND application and trial initiation. The ongoing first-in-human Phase 1 study began recruiting patients in the United States in August 2025, with initial clinical data expected by mid-2026.EU-StartupsSwiss BioTech FoRx Therapeutics closes €42 million for next-generation DNA repair cancer therapyFoRx Therapeutics, a Basel-based clinical-stage BioTech company, has closed €42 million in Series A financing to advance its DNA repair cancer therapy FORX-428. The funds will support ongoing Phase 1 trials of the drug, which has shown promising anti-tumor efficacy in preclinical models, with expected initial clinical data in mid-2026. This funding round is part of a broader trend of increased investment in European oncology-focused BioTech companies in 2025.FinSMEsFoRx Therapeutics Raises USD50M in Series A FinancingFoRx Therapeutics closed a USD50M Series A financing, with backers including EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund, and M Ventures. The funds will advance Phase 1 clinical development of its lead drug candidate FORX-428, a PARG inhibitor for advanced solid tumors.GlobeNewswireFoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG InhibitorFoRx Therapeutics closed a USD 50 million Series A financing to advance Phase 1 clinical development of its lead PARG inhibitor candidate FORX-428. The funding will support the ongoing open-label Phase 1 study in advanced solid tumors, with initial data expected in mid-2026. The company aims to treat patients whose cancers are resistant to PARP inhibitors.YahooFoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG InhibitorFoRx Therapeutics announced closing of a USD 50 million Series A financing to support Phase 1 development of its PARG inhibitor FORX-428. The company aims to establish the drug as a treatment option for cancers resistant to PARP inhibitors, with initial data expected in mid-2026 from a US study.GlobeNewswireFoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG InhibitorFoRx Therapeutics announced the close of a USD 50 million Series A financing to advance Phase 1 clinical development of FORX-428, a potential best-in-class PARG inhibitor targeting DNA Damage Response in advanced solid tumors. The funding will support the ongoing first-in-human Phase 1 study, with initial clinical data readout expected by mid-2026 from the open-label trial in the United States. The drug candidate is positioned as a next-generation treatment option for patients whose cancers are resistant to or have become resistant to PARP inhibitors.BioSpaceFoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG InhibitorFoRx Therapeutics announced the close of a USD 50 million Series A financing to advance Phase 1 clinical development of FORX-428, a potential best-in-class PARG inhibitor targeting DNA Damage Response in advanced solid tumors. The funding, led by existing investors EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund, and M Ventures, will enable initial clinical data readout expected in mid-2026 from the ongoing open-label study in patients with advanced solid tumors in the United States. The PARG inhibitor candidate targets patients whose cancers have become resistant to PARP inhibitors, representing a next-generation approach in precision oncology.